中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.017 seconds)

    ANAPLEROTIC THERAPY FOR ALZHEIMER'S DISEASE AND THE AGING BRAIN
    1.
    发明申请
    ANAPLEROTIC THERAPY FOR ALZHEIMER'S DISEASE AND THE AGING BRAIN 审中-公开

    公开(公告)号：US20190388379A1

    公开(公告)日：2019-12-26

    申请号：US16364810

    申请日：2019-03-26

    Applicant: Baylor Research Institute

    Inventor： Charles R. ROE ,  Teodoro G. BOTTIGLIERI

    IPC: A61K31/23

    Abstract: The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone bodies, reduces amyloid-β (Aβ) deposition in AD patients, thereby improving cognition and locomotive skills.

    FATTY ACID TREATMENT FOR CARDIAC PATIENTS
    4.
    发明申请
    FATTY ACID TREATMENT FOR CARDIAC PATIENTS 审中-公开

    公开(公告)号：US20190038585A1

    公开(公告)日：2019-02-07

    申请号：US16100771

    申请日：2018-08-10

    Applicant: Baylor Research Institute

    Inventor： Charles R. ROE

    IPC: A61K31/20 ,  A61K31/19 ,  A61K31/23 ,  A61K31/194

    Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

    FATTY ACID TREATMENT FOR CARDIAC PATIENTS
    10.
    发明申请
    FATTY ACID TREATMENT FOR CARDIAC PATIENTS 审中-公开

    公开(公告)号：US20170333376A1

    公开(公告)日：2017-11-23

    申请号：US15587236

    申请日：2017-05-04

    Applicant: Baylor Research Institute

    Inventor： Charles R. ROE

    IPC: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

    CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

    Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

Patent Agency Ranking